New England, New York and Quebec Regional Clinical Center
新英格兰、纽约和魁北克地区临床中心
基本信息
- 批准号:7475109
- 负责人:
- 金额:$ 31.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-30 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:Advanced Glycosylation End ProductsAgonistAnti-Inflammatory AgentsAnti-inflammatoryBiological MarkersBiopsyBloodBlood VesselsCardiac Surgery proceduresClinicalClinical ResearchClinical TrialsCollagenCommitDefectDiabetes MellitusDiseaseElementsEnrollmentFunctional disorderGoalsHealthcareHeartHeart failureHuman ResourcesHypertensionIn VitroInflammationInflammatoryInstitutionInsulin ResistanceMassachusettsMedical centerMetabolicMethodsMyocardialMyocardiumNew EnglandNew YorkNon-Insulin-Dependent Diabetes MellitusOperative Surgical ProceduresOutcomeOxidative StressParticipantPatientsPeroxisome Proliferator-Activated ReceptorsPharmaceutical PreparationsPopulationPrivate PracticePropertyQuebecRiskRisk FactorsSkinStagingThinkingTreatment ProtocolsUniversitiesVermontabstractingadiponectincrosslinkdiabetic cardiomyopathyexperiencefollow-uphospital bedimprovedrandomized placebo controlled trialrural areatertiary care
项目摘要
DESCRIPTION (provided by applicant):
This is an application for designation as a Regional Clinical Center (RCC) of the Heart Failure (HF) Clinical Research Network. The participants are a diverse group of institutions in Northern New England, New York and Quebec, including the University of Vermont/Fletcher Allen Health Care (the sponsoring institution), Albany/St. Peter's Medical Centers, Catholic Medical Center, Dartmouth-Hitchcock Medical Center, McGill Medical Center and Univ. of Massachusetts Medical Center. The proposed RCC has a tertiary care catchment population over 6,000,000 and over 3,500 hospital beds. In 2004, over 2300 new patients with HF were seen, and over 180 follow-up patients with HF were seen weekly. The RCC also includes cardiologists in private practice in Vermont and New York who are committed to enrolling patients from rural areas who rarely participate in clinical trials. Key personnel have extensive experience in planning and management of multi-center trials and local PIs at each institution are experienced participants. Various collaborative activities are planned to maintain a vibrant regional network. The two proposed projects for the RCC share a. common theme, type 2 diabetes mellitus (DM) as a risk factor for and mechanism of HF. Project #1 is a placebo-controlled, randomized trial of a thiazalodinedione to treat diastolic dysfunction (DD), a common and
early manifestation of diabetic cardiomyopathy. Secondary outcomes are systolic dysfunction and changes in blood levels of pro-inflammatory and pro-fibrotic biomarkers. Project #2 employs methods we have developed to study "skinned" strips of myocardium obtained during cardiac surgery as well as from endstage, explanted hearts. By using surgical biopsies, we can examine non-end stage disease states that can cause HF and delineate disease-specific elements of pathophysiology and drug effects. We will use these methods to determine the in vitro, disease-specific effects of the drug Alagebrium, a breaker of advanced glycation end-product (AGE) associated collagen cross-links, on passive stiffness in patients with DM, hypertension (HTN) and DM + HTN. AGEs are thought to cause increased myocardial and vascular stiffness in these patients. Results will be correlated with pre-operative DD and assessment of AGEs by immuno electronmicroscopy. The studies we propose for our RCC have potential to reduce the risk of HF in patients with DM. Biopsy studies will improve understanding of pathophysiology and drug effects and mechanisms. (End of Abstract)
描述(由申请人提供):
这是心力衰竭(HF)临床研究网络指定为区域临床中心(RCC)的申请。参与者来自北方新英格兰、纽约和魁北克的各种机构,包括佛蒙特大学/弗莱彻艾伦保健中心(赞助机构)、奥尔巴尼/圣彼得医疗中心、天主教医疗中心、达特茅斯-希区柯克医疗中心、麦吉尔医疗中心和马萨诸塞州大学医疗中心。拟议的区域康复中心有一个三级保健服务区,人口超过600万,医院床位超过3,500张。在2004年,超过2300名新的HF患者被发现,每周超过180名随访的HF患者被发现。RCC还包括佛蒙特州和纽约私人执业的心脏病专家,他们致力于招募来自农村地区的患者,这些患者很少参加临床试验。关键人员在多中心试验的规划和管理方面具有丰富的经验,每个机构的当地PI都是经验丰富的参与者。计划开展各种合作活动,以维持一个充满活力的区域网络。区域合作委员会的两个拟议项目有一个共同点。共同的主题,2型糖尿病(DM)作为HF的危险因素和机制。项目#1是一项安慰剂对照的随机试验,研究噻唑烷二酮治疗舒张功能障碍(DD),一种常见的
糖尿病心肌病的早期表现。次要结局是收缩功能障碍和促炎性和促纤维化生物标志物的血液水平变化。项目#2采用我们开发的方法来研究心脏手术期间以及从终末期心脏中获得的“皮肤”心肌条。通过使用手术活检,我们可以检查非终末期疾病状态,可以导致HF和描绘疾病的病理生理学和药物作用的特定元素。我们将使用这些方法来确定药物Alagelatin(一种晚期糖基化终产物(AGE)相关胶原交联的破坏剂)对DM、高血压(HTN)和DM + HTN患者被动僵硬的体外疾病特异性作用。AGEs被认为会导致这些患者的心肌和血管僵硬度增加。结果将与术前DD和免疫电镜评估AGEs相关。我们为RCC提出的研究有可能降低DM患者的HF风险。活检研究将提高对病理生理学和药物作用和机制的理解。 (End摘要)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN M LEWINTER其他文献
MARTIN M LEWINTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN M LEWINTER', 18)}}的其他基金
CLINICAL TRIAL: PHOSPHODIESTE RASE-5 INHIBITION IN DIASTOLIC HEART FAILURE (RELA
临床试验:磷酸二酯酶 5 抑制舒张性心力衰竭 (RELA
- 批准号:
8166988 - 财政年份:2010
- 资助金额:
$ 31.12万 - 项目类别:
CLINICAL TRIAL: PHOSPHODIESTE RASE-5 INHIBITION IN DIASTOLIC HEART FAILURE (RELA
临床试验:磷酸二酯酶 5 抑制舒张性心力衰竭 (RELA
- 批准号:
7952127 - 财政年份:2009
- 资助金额:
$ 31.12万 - 项目类别:
Advanced Glycation End-Products in Human Myocardium
人心肌中的高级糖基化终产物
- 批准号:
7686199 - 财政年份:2008
- 资助金额:
$ 31.12万 - 项目类别:
Advanced Glycation End-Products in Human Myocardium
人心肌中的高级糖基化终产物
- 批准号:
7923815 - 财政年份:2008
- 资助金额:
$ 31.12万 - 项目类别:
Advanced Glycation End-Products in Human Myocardium
人心肌中的高级糖基化终产物
- 批准号:
8133872 - 财政年份:2008
- 资助金额:
$ 31.12万 - 项目类别:
Advanced Glycation End-Products in Human Myocardium
人心肌中的高级糖基化终产物
- 批准号:
7474447 - 财政年份:2008
- 资助金额:
$ 31.12万 - 项目类别:
New England, New York and Quebec Regional Clinical Center
新英格兰、纽约和魁北克地区临床中心
- 批准号:
7114564 - 财政年份:2006
- 资助金额:
$ 31.12万 - 项目类别:
New England, New York and Quebec Regional Clinical Center
新英格兰、纽约和魁北克地区临床中心
- 批准号:
7289791 - 财政年份:2006
- 资助金额:
$ 31.12万 - 项目类别:
New England, New York and Quebec Regional Clinical Center
新英格兰、纽约和魁北克地区临床中心
- 批准号:
7653705 - 财政年份:2006
- 资助金额:
$ 31.12万 - 项目类别:
New England, New York and Quebec Regional Clinical Center
新英格兰、纽约和魁北克地区临床中心
- 批准号:
7881714 - 财政年份:2006
- 资助金额:
$ 31.12万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 31.12万 - 项目类别: